All News

Previously, felzartamab received orphan drug designation and breakthrough therapy designation for the treatment of primary membranous nephropathy.

Evidence suggests foods that activate sirtuin proteins may be beneficial for metabolic syndromes

Pembrolizumab in combination with chemotherapy followed by maintenance olaparib did not meet its pre-specified statistical criteria of overall survival or progression free survival.

After years of seeking the right position, one technician combines her passions and skills as an inventory specialist

Melatonin is linked to circadian rhythm, mitochondrial function, and neuroinflammation.

The podcast discusses how City of Hope Chicago fully integrates oncology pharmacists into care teams by positioning them in clinics, improving communication and collaboration to minimize delays for patients and enhance care delivery.

The state order was signed on Tuesday and is just a part of an overall mission to strengthen and protect reproductive rights within New York for citizens and those out of state.

The orphan drug designation (ODD) comes after positive results from a phase 2 trial that showed cevidoplenib improved platelet counts by 63.6% and 40.9% in 2 different dose groups.

The combination tablet (Opsynvi; Johnson & Johnson) can also be used for individuals with pulmonary arterial hypertension who are being treated with stable doses of macitentan and tadalafil as separate tables.

Zero relapses were reported among individuals that received ravulizumab-cwvz over the 73 weeks of treatment.

The indication is for adults and adolescents with moderate to severe immune compromise due to medical conditions or immunosuppressive medications and treatments.

The orphan drug designation (ODD) is a result of positive findings from a phase 2 clinical trial which demonstrated a 100% clinical benefit rate in patients.

Fortification with folic acid may be especially beneficial in countries that do not have mandated folic acid fortification regulations.

The test’s sensitivity in distinguishing colorectal cancer, in combination with real-world adherence, showed its ability to detect cancer at a curable stage.

PT886 (Phanes Therapeutics) received fast track designation 2 years after receiving orphan drug designation by the FDA.

An FDA executive discusses the Surgeon General’s recommendations for promoting mental health and wellbeing for employees in the workplace.

A pharmacist discusses the impact of comprehensive weight management with a shared decision making approach.

These therapies can improve treatment adherence for patients, especially for those with a history of poor or uncertain adherence.

Studies have shown that the presence of advanced pharmacy technicians in a pharmacy has a positive predictive validity to increased monthly immunizations.

Food pharmacies, in particular, can be a great opportunity for pharmacists to collaborate with other providers, improve access to nutritious foods, and find unique opportunities to counsel patients.

Shared decision making with patients is a key component of RSV vaccination, which can bring challenges and opportunities.

In addition to improved efficacy, newer generations of anti-obesity medications have significantly improved safety concerns.

Sa'ed Al-Olimat, PharmD, also discussed the potentially groundbreaking shift for MDMA expected later in 2024.

Pharmacogenomics could help streamline prescribing and dosing for psychiatric medications, avoiding the trial-and-error process common with these medications.

Pharmacists can educate patients on current clinical evidence of cannabis’s therapeutic benefit, as well as cannabis’s complexities, risks, and potential adverse effects.

Expert Jennifer Clements discussed the evolving landscape of weight management medications, clinical considerations, and obstacles to use.

Bempedoic acid (Nexletol; Esperion) and bempedoic acid and ezetimibe (Nexlizet; Esperion) are the only LDL-C lowering non-statin drugs indicated for primary prevention patients.

The treatment is indicated for patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers.